|
Illumina Paves “Roadmap” to NGS Use in Clinical Settings
Genetic Engineering News In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform. The product, Illumina asserts, will be faster, less expensive, and more … |
Preventing Cell Death from Infection: Scientists Demonstrate Method to Find … – Infection Control Today
|
Preventing Cell Death from Infection: Scientists Demonstrate Method to Find …
Infection Control Today Scientists at the Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find—relatively quickly and cheaply—antibodies that have a desired effect on cells. The TSRI scientists used the … |
Bollywood actress Suchitra Sen dies at 82 of heart failure – Fox News
Gulf Times |
Bollywood actress Suchitra Sen dies at 82 of heart failure
Fox News Suchitra Sen, a legendary Indian actress known for her memorable roles in both Bengali-language and Hindi Bollywood films, died Friday of heart failure. She was 82. Sen was hospitalized in Kolkata more than three weeks ago for treatment of a … Actress Suchitra Sen dies of heart failureGulf Times Bollywood’s yesteryear actress Suchitra Sen dies at age 82Vancouver Desi |
Illumina (ILMN) Updates on Road Map at Investor Day – StreetInsider.com (subscription)
|
Illumina (ILMN) Updates on Road Map at Investor Day
StreetInsider.com (subscription) In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform that will be faster, less expensive, and more accurate than current … |
2014 Outlook: New Drugs in Hepatitis C, MS, Oncology Are Expected This Year – Atlantic Information Services, Inc.
|
2014 Outlook: New Drugs in Hepatitis C, MS, Oncology Are Expected This Year
Atlantic Information Services, Inc. … to approve it (see story, p. 1). Other potential additions, she says, include Teva’s laquinimod, Biogen Idec and Abbott Laboratories’ daclizumab and ocrelizumab from Biogen Idec and Roche. © 2014 by Atlantic Information Services, Inc. All Rights … |
MidMichigan nurse practitioner trained at University of Michigan Health System … – Midland Daily News
MidMichigan nurse practitioner trained at University of Michigan Health System …Midland Daily NewsLast year, Jennifer Dankers, a MidMichigan Physicians Group nurse practitioner specializing in congestive heart failure, began collaborating with the Un…
Dutchy blasts Jets after Heart failure: photos – Newcastle Herald
|
Dutchy blasts Jets after Heart failure: photos
Newcastle Herald Dutchy blasts Jets after Heart failure: photos. By JAMES GARDINER. Jan. 17, 2014, 11 p.m.. THE Newcastle Jets’ season is in danger of entering free fall after they suffered the embarrassment of being the first team to lose to Melbourne Heart in almost … |
Robot-Assisted Partial Nephrectomy Minimizes Loss of Kidney Function in … – AZoRobotics
Robot-Assisted Partial Nephrectomy Minimizes Loss of Kidney Function in …AZoRoboticsPatients with chronic kidney disease who received robot-assisted partial nephrectomy to treat kidney cancer have minimal loss of kidney function — a smaller amount e…
Mom's persistence leads to baby's 'miracle' recovery – Sun-Sentinel
Sun-Sentinel |
Mom’s persistence leads to baby’s ‘miracle’ recovery
Sun-Sentinel A Pembroke Pines girl who defied the odds by surviving a high-risk transplant surgery is once again surprising doctors with a will to live that even a rare inherited disease can’t conquer. A year after Izabella Neira became one of the youngest patients … |
Biogen Idec-Aktie: Prall gefüllte Pipeline – Kaufen – Nomura Securties … – AktienCheck
|
Biogen Idec-Aktie: Prall gefüllte Pipeline – Kaufen – Nomura Securties …
AktienCheck Der Fokus von Aktienanalyst M. Ian Somaiya liege für das Börsenjahr 2014 auf den Phase-III MS Daten der USD 2 Mrd.-Chance daclizumab zur Jahresmitte und den anti-LINGO-Phase-II-Daten im vierten Quartal 2014. Aktienanalyst M. Ian Somaiya … |